Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 30243312.
- Also identified by DOI 10.1016/j.kint.2018.06.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Use of calcimimetics will be influenced not only by assessment of benefits and harms in individual patients but also by cost and by national guidelines. The Japanese Society for Dialysis Therapy has a lower PTH threshold for PTH control than other countries. The current RCT, despite its limitations, provides a rationale for use of evocalcet in the management of secondary hyperPTH.
Medical subject headings
- Cinacalcet
- Hyperparathyroidism, Secondary